Effect of Super-GDF9 on CAPA-IVM of COCs From Small Antral Follicles

Launched by MỸ ĐỨC HOSPITAL · Jan 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to improve in vitro maturation (IVM) for women undergoing in vitro fertilization (IVF), especially those who may be at higher risk for complications. The researchers are looking at the effects of a special growth factor called super GDF9, which may help enhance the quality of eggs (oocytes) developed from small follicles. The goal is to see if adding super GDF9 during the egg maturation process can lead to better outcomes, such as more high-quality embryos and increased chances of successful pregnancies.

To participate in the trial, women need to be between 18 and 38 years old, have a body mass index (BMI) of 32 or less, and have polycystic ovary syndrome (PCOS) as defined by certain criteria. They should also have a specific hormone level and a certain number of small follicles in their ovaries. Participants will be asked to donate their eggs for research, agree to have frozen embryos, and provide consent before starting any study-related procedures. This trial offers an opportunity to contribute to research that could improve fertility treatments for many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women between the ages of 18 and 38 years (both inclusive)
• • 2. BMI ≤ 32 kg/m2
• • 3. PCOS women according to the Rotterdam criteria (2003)
• • 4. Indicating CAPA-IVM treatment.
• • 5. Serum AMH ≥ 4 ng/mL (28.57 pmol/L) at screening and having at least 24 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication
• • 6. Willing to donate COCs for research purposes
• • 7. Agreeing for frozen embryo
• • 8. Signed informed consent before any study-related procedures
• Exclusion Criteria:
• • 1. Known endometrioma or grade 3-4 endometriosis according to ASRM classification
• • 2. Uterine abnormalities
• • 3. Couples with severe male factor (sperm concentration \<5 million/ml, motility \< 10%), surgical sperm retrieval.
• • 4. Previous history of unexplained immature oocytes after IVF treatment
• • 5. Cycles using donor oocytes